Blockbuster Drugs

The Rise and Decline of the Pharmaceutical Industry

Nonfiction, Health & Well Being, Medical, Medical Science, Pharmacology
Cover of the book Blockbuster Drugs by Jie Jack Li, Oxford University Press
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: Jie Jack Li ISBN: 9780199911929
Publisher: Oxford University Press Publication: December 2, 2013
Imprint: Oxford University Press Language: English
Author: Jie Jack Li
ISBN: 9780199911929
Publisher: Oxford University Press
Publication: December 2, 2013
Imprint: Oxford University Press
Language: English

For the world's largest prescription drug manufacturers, the last few years have been a harrowing time. Recently, Pfizer's Lipitor, GlaxoSmithKline's Advair, AstraZeneca's Seroquel, and Sanofi-Aventis and Bristol-Myers Squibb's Plavix all came off patent in the crucial U.S. market. This so-called "patent cliff" meant hundreds of billions of dollars in lost revenue and has pharmaceutical developers scrambling to create new drugs and litigating to extend current patent protections. Having spent most of his career in drug discovery in "big pharma," Dr. Li now delivers an insider's account of how the drug industry ascended to its plateau and explores the nature of the turmoil it faces in the coming years. He begins with a survey of the landscape before "blockbuster drugs," and proceeds to describe how those drugs were discovered and subsequently became integral to the business models of large pharmaceutical companies. For example, in early 1980s, Tagamet, the first "blockbuster drug," transformed a minor Philadelphia-based drug maker named SmithKline & French into the world's ninth-largest pharmaceutical company in terms of sales. The project that delivered Tagamet was nearly terminated several times because research efforts begun in 1964 produced no apparent results within the first eleven years. Similar stories accompany the discovery and development of now-ubiquitous prescription drugs, among them Claritin, Prilosec, Nexium, Plavix, and Ambien. These stories, and the facets of the pharmaceutical industry that they reveal, can teach us valuable lessons and reveal many crucial aspects about the future landscape of drug discovery. As always, Dr. Li writes in a readable style and intersperses fascinating stories of scientific discovery with engaging human drama.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

For the world's largest prescription drug manufacturers, the last few years have been a harrowing time. Recently, Pfizer's Lipitor, GlaxoSmithKline's Advair, AstraZeneca's Seroquel, and Sanofi-Aventis and Bristol-Myers Squibb's Plavix all came off patent in the crucial U.S. market. This so-called "patent cliff" meant hundreds of billions of dollars in lost revenue and has pharmaceutical developers scrambling to create new drugs and litigating to extend current patent protections. Having spent most of his career in drug discovery in "big pharma," Dr. Li now delivers an insider's account of how the drug industry ascended to its plateau and explores the nature of the turmoil it faces in the coming years. He begins with a survey of the landscape before "blockbuster drugs," and proceeds to describe how those drugs were discovered and subsequently became integral to the business models of large pharmaceutical companies. For example, in early 1980s, Tagamet, the first "blockbuster drug," transformed a minor Philadelphia-based drug maker named SmithKline & French into the world's ninth-largest pharmaceutical company in terms of sales. The project that delivered Tagamet was nearly terminated several times because research efforts begun in 1964 produced no apparent results within the first eleven years. Similar stories accompany the discovery and development of now-ubiquitous prescription drugs, among them Claritin, Prilosec, Nexium, Plavix, and Ambien. These stories, and the facets of the pharmaceutical industry that they reveal, can teach us valuable lessons and reveal many crucial aspects about the future landscape of drug discovery. As always, Dr. Li writes in a readable style and intersperses fascinating stories of scientific discovery with engaging human drama.

More books from Oxford University Press

Cover of the book The Fundamental Wisdom of the Middle Way by Jie Jack Li
Cover of the book Crime & Politics by Jie Jack Li
Cover of the book Sri Lanka in the Modern Age by Jie Jack Li
Cover of the book Children of the Prison Boom by Jie Jack Li
Cover of the book Melancholic Modalities by Jie Jack Li
Cover of the book Bringing technology into the classroom - Into the Classroom by Jie Jack Li
Cover of the book Gifts by Jie Jack Li
Cover of the book Roosevelt's Second Act by Jie Jack Li
Cover of the book Global Pentecostal and Charismatic Healing by Jie Jack Li
Cover of the book Journalism Without Profit by Jie Jack Li
Cover of the book Learning Technology by Jie Jack Li
Cover of the book The Betrayal by Jie Jack Li
Cover of the book Why Occupy a Square? by Jie Jack Li
Cover of the book Anselm by Jie Jack Li
Cover of the book Conditional Reasoning by Jie Jack Li
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy